Winslow Evans & Crocker’s Clovis Oncology, Inc. CLVS Stock Holding History

Winslow Evans & Crocker’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$8K	Buy	1,580 +800	+103%	+$4.05K	﹤0.01%	1007
2020 Q3	$5K	Sell	780 -100	-11%	-$598	﹤0.01%	896
2020 Q2	$6K	Hold	880	–	–	﹤0.01%	866
2020 Q1	$8K	Sell	880 -600	-41%	-$4.81K	﹤0.01%	782
2019 Q4	$18K	Buy	1,480 +480	+48%	+$3.49K	﹤0.01%	700
2019 Q3	$4K	Hold	1,000	–	–	﹤0.01%	1044
2019 Q2	$16K	Hold	1,000	–	–	﹤0.01%	731
2019 Q1	$26K	Hold	1,000	–	–	0.01%	621
2018 Q4	$18K	Sell	1,000 -1,400	-58%	-$28.6K	0.01%	651
2018 Q3	$72K	Hold	2,400	–	–	0.02%	427
2018 Q2	$110K	Buy	2,400 +100	+4%	+$4.86K	0.03%	356
2018 Q1	$121K	Hold	2,300	–	–	0.04%	324
2017 Q4	$156K	Buy	2,300 +700	+44%	+$48.9K	0.05%	297
2017 Q3	$132K	Buy	1,600 +600	+60%	+$47.6K	0.04%	310
2017 Q2	$93.6K	Buy	+1,000	New	+$61.2K	0.03%	444

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Winslow Evans & Crocker's CLVS Position: Q4 2020 in Review

Winslow Evans & Crocker increased its Clovis Oncology, Inc. (CLVS) stake by 103% in Q4 2020, buying an estimated $4.05K and bringing the position to 1,580 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #1007.

Winslow Evans & Crocker first reported a position in CLVS in Q2 2017 and has held it in 15 quarters since. The position peaked at $156K in Q4 2017. 159 funds tracked by Wall St. Rank hold CLVS as of Q4 2020.

Winslow Evans & Crocker held 1,580 shares of Clovis Oncology, Inc. worth $8K as of Q4 2020.
Winslow Evans & Crocker bought 800 Clovis Oncology, Inc. shares in Q4 2020, an estimated $4.05K.
Clovis Oncology, Inc. made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #1007 holding.
Winslow Evans & Crocker first reported a position in Clovis Oncology, Inc. in Q2 2017 and has held it in 15 quarters since.
Winslow Evans & Crocker's Clovis Oncology, Inc. position peaked at $156K in Q4 2017.
159 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.